Riskpilot← Back to searchSign inGet full accessVet InVitro ApS
APSActiveCVR 39806797Hovedgaden 55Veterinary activities · NACE 7500Est. 2018— employees
Revenue 2024
DKK 9K
-97% vs 2023
EBITDA margin
100.0%
-97% vs 2023
Equity ratio
-185.0%
Financial strength
Net profit 2024
DKK -311K
-838% vs 2023
| Revenue | DKK 9K | -97% |
| EBITDA | DKK 9K | -97% |
| Net profit | DKK -311K | -838% |
| Total assets | DKK 383K | -66% |
| Equity | DKK -709K | -78% |
| Employees | — | — |
Legal name
Vet InVitro ApS
CVR number
39806797
Legal form
Anpartsselskab
NACE code
7500 · Veterinary activities
Founded
23. august 2018
Share capital
DKK 40.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to direktører i forening.
Company purpose
Selskabets formål er at udbyde veterinære laboratorieydelser samt andre beslægtede ydelser efter direktionens skøn.
Address
Hovedgaden 55
Phone
+4540791520
Email
emma@vetinvitro.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -156 | 384 | -0 | 293 | 271 | 9 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -156 | 310 | -0 | 293 | 271 | 9 |
| Depreciation & amort. | -83 | -126 | -213 | -248 | -253 | -258 |
| EBIT | -239 | 184 | -213 | 45 | 19 | -249 |
| Net financials | -33 | -59 | -45 | -45 | -52 | -62 |
| Profit before tax | -272 | 125 | -258 | -0 | -33 | -311 |
| Tax | 8 | -8 | -0 | -0 | -0 | -0 |
| Net profit | -280 | 133 | -258 | -0 | -33 | -311 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 708 | 874 | 899 | 1.066 | 1.141 | 383 |
| Equity | -275 | -142 | -364 | -364 | -398 | -709 |
| Long-term debt | 0 | 0 | 165 | 118 | 68 | 118 |
| Short-term debt | 975 | 1.015 | 1.098 | 1.312 | 1.471 | 974 |
| Total debt | 975 | 1.015 | 1.263 | 1.430 | 1.539 | 1.092 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20192024
Equity ratio
-185.0%
This company
38.2%
Market median
-584% vs market
20192024
Return on equity
-31135000.0%
This company
18.4%
Market median
-169212057% vs market
20192024
Net profit margin
-3445.3%
This company
8.1%
Market median
-42635% vs market
20192024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20192024
Debt / equity
1.54×
This company
0.62×
Market median
-148% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-08-23 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EK Management | Management | 2018 | — | — |
AC Management | Management | 2018 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
EAC Holding ApS | Company | 100.0% | 100.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
EAC Holding ApS
Vet InVitro ApS Board members of Vet InVitro ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emma Kathrine Lorenzen | Management | 0 companies |
| Andreas Carstensen | Management | 0 companies |